Skip to main content
MorphoSys AG logo

MorphoSys AG — Investor Relations & Filings

Ticker · MOR ISIN · DE000A3H2XW6 LEI · 529900493806K77LRE72 F Manufacturing
Open in API
Filings indexed 1,418 across all filing types
Latest filing 2017-11-30 Declaration of Voting R…
Country DE Germany
Listing F MOR

About MorphoSys AG

https://www.morphosys.com/

MorphoSys AG is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines, primarily for cancer patients. The company specializes in creating therapeutic monoclonal antibodies, utilizing its long-standing expertise and proprietary technology platforms to generate fully human antibodies. Its research and development efforts are concentrated on building a pipeline of novel treatments to address significant unmet medical needs in oncology. In February 2024, Novartis entered into an agreement to acquire MorphoSys, aiming to integrate its antibody technologies and oncology pipeline.

Recent filings

Filing Released Lang Actions
Release according to Article 26a of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled 'MorphoSys AG: Release according to Article 26a of the WpHG' and explicitly announces the 'Publication of total number of voting rights' as of 30.11.2017. It details a 'Conditional capital increase' and states the 'New total number of voting rights: 29.419.285'. This content directly relates to changes in the capital structure and the resulting voting rights, which aligns best with the 'Capital/Financing Update' (CAP) definition, as it concerns a capital measure (conditional increase) affecting the total voting rights. While it involves voting rights, it is not the *results* of a shareholder vote (DVA), but rather an announcement about the total number of shares/rights due to a capital action. It is a specific regulatory disclosure regarding capital structure.
2017-11-30 English
MorphoSys Signs Regional License Agreement for Antibody MOR202 with I-Mab (news with additional features)
Earnings Release Classification · 99% confidence The document is a press release dated November 30, 2017, announcing a 'Regional License Agreement for Antibody MOR202 with I-Mab'. It details financial terms (upfront payment, royalties, milestones) and includes an update to the company's 2017 financial guidance (revenues and EBIT). This content is characteristic of an Earnings Release (ER) or a significant corporate/financial announcement that is not a full statutory report (like 10-K or IR). Since it announces key financial results/updates (guidance increase) alongside a major business event (licensing deal), it fits best under Earnings Release (ER) as it provides the immediate financial impact and highlights, or potentially Regulatory Filings (RNS) if it's primarily a business update. Given the explicit mention of increasing financial guidance for the year, ER is a strong candidate, but since it's structured as a general news release (DGAP-News) announcing a partnership and subsequent guidance change, it is most accurately classified as a general Regulatory Filing (RNS) or a specific announcement that doesn't fit the strict definitions of ER (which usually focuses only on period results) or CAP (which focuses on fundraising/capital structure). However, because it contains a direct update to financial guidance ('MorphoSys increases its financial guidance for 2017'), it strongly aligns with the purpose of an Earnings Release (ER) which often accompanies or includes such forward-looking adjustments. Since it is not a full quarterly report (IR) or a formal earnings release document structure, and it is a general news announcement, RNS is the safest fallback. But, the guidance update makes ER highly relevant. Given the context of major corporate news that impacts financials, and the structure being a news release (not a formal 10-Q/10-K), I will classify it as a Regulatory Filing (RNS) as it is a general corporate announcement distributed via DGAP, which is listed as a service for 'Regulatory Announcements, Financial/Corporate News and Press Releases'. FY 2017
2017-11-30 English
Ad hoc: MorphoSys Increases Financial Guidance for 2017 Following Signature of Regional License Agreement for Antibody MOR202 with I-Mab
Earnings Release Classification · 99% confidence The document is an 'Ad-hoc' announcement dated November 30, 2017, disclosing inside information according to Article 17 MAR (Market Abuse Regulation). The core content is the announcement of a regional license agreement and, crucially, the subsequent increase in the company's financial guidance for 2017 (revenues and EBIT). This type of immediate, material financial update, which is not a full periodic report (like 10-K or IR) but rather a specific, material event disclosure, fits best under the 'Earnings Release' (ER) category if it contains updated financial metrics, or 'Regulatory Filings' (RNS) as a general disclosure. Since it explicitly updates financial guidance ('MorphoSys Increases Financial Guidance for 2017') based on a new agreement, it is closely related to earnings/financial performance updates. However, it is primarily a disclosure of a significant corporate event (licensing deal) that *causes* a guidance change, rather than a standard quarterly earnings release. Given the options, and recognizing this is a mandatory, immediate disclosure of material non-public information (Ad hoc/MAR 17), it is most accurately classified as a general Regulatory Filing (RNS) or potentially an Earnings Release (ER) due to the explicit guidance revision. Since it is not a standard quarterly/annual report, and the primary driver is the licensing deal, RNS is the safest fallback for a specific, non-standard regulatory disclosure. However, because it contains specific updated revenue and EBIT figures, ER is also plausible. Given the structure of the definitions, where ER is for 'Initial announcement of quarterly/periodical financial results (key highlights only)', and this is an *unscheduled* update based on a deal, RNS (General regulatory announcements and fallback category) is the most appropriate fit for a MAR Article 17 disclosure that isn't a standard earnings report. FY 2017
2017-11-30 English
DGAP-DD: MorphoSys AG english
Director's Dealing Classification · 100% confidence The document is explicitly titled 'Directors’ Dealings' and contains a section titled 'Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them'. It details the name of the person (Dr. Markus Enzelberger), their position ('Member of the managing body'), the nature of the transaction ('Disposal'), and specific price and volume data for share transactions. This content directly corresponds to the definition of Director's Dealing reports.
2017-11-23 English
DGAP-DD: MorphoSys AG english
Director's Dealing Classification · 100% confidence The document is explicitly titled 'Directors’ Dealings' and contains a section 'Notification and public disclosure of transactions by persons discharging managerial responsibilities'. It details a transaction (Purchase of shares) by a member of the managing body (Dr. Markus Enzelberger) of MorphoSys AG. This directly corresponds to the definition of Director's Dealing, which is classified under the code DIRS.
2017-11-23 English
MorphoSys Announces That Its Licensee Janssen Has Received Approval for Tremfya(R) (Guselkumab) in Europe for the Treatment of Moderate-to-Severe Plaque Psoriasis (news with additional features)
Regulatory Filings Classification · 100% confidence The document is a press release dated November 23, 2017, announcing that MorphoSys's licensee, Janssen, received approval for the drug Tremfya (Guselkumab) in Europe for treating plaque psoriasis. It details the significance of the approval, the company's royalty entitlement, and includes standard corporate boilerplate information. This type of announcement, focusing on a specific regulatory event (drug approval) and its immediate business impact, is best classified as a general Regulatory Filing or News Release, as it doesn't fit the specific definitions for Earnings Release (ER), Interim Report (IR), or Capital Update (CAP). Given the options, 'Regulatory Filings' (RNS) serves as the most appropriate general category for significant, non-standard regulatory news that isn't a core financial report or management change.
2017-11-23 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.